GetTopicDetailResponse(id=85dc4340cd, topicName=CD47單抗, introduction=CD47單抗, content=null, image=null, comments=1, allHits=1160, url=https://h5.medsci.cn/topic?id=4340, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=80230, tagList=[TagDto(tagId=80230, tagName=CD47單抗)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2106186, encodeId=cf8221061862d, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a><a href='/topic/show?id=85dc4340cd' target=_blank style='color:#2F92EE;'>#CD47單抗#</a><a href='/topic/show?id=c94a1050e951' target=_blank style='color:#2F92EE;'>#Magrolimab#</a>為基礎(chǔ)的三聯(lián)治療在<a href='/topic/show?id=11fe2435ff' target=_blank style='color:#2F92EE;'>#AML#</a>中取得顯著突破, objectTitle=ASH 2022：武田CD47單抗Magrolimab為基礎(chǔ)的三聯(lián)治療在AML中取得顯著突破, objectType=article, longId=751774, objectId=3e09e5177482, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20221123/31323a17ac4d4b7494651c06a4fd8df8.jpg, objectUrl=/article/show_article.do?id=3e09e5177482, replyNumber=0, likeNumber=166, createdTime=2022-12-15, rootId=0, userName=俠膽醫(yī)心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=3e09e5177482, moduleTitle=ASH 2022：武田CD47單抗Magrolimab為基礎(chǔ)的三聯(lián)治療在AML中取得顯著突破, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=3e09e5177482)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
